Euroviews: Why Europe Struggles to Turn World-Class Science Into Business
Poinews.com – Why Europe struggles to turn world-class science into business is a pressing issue that continues to shape the continent’s innovation landscape. While Europe remains a global leader in research and development, its ability to translate scientific breakthroughs into commercial success has lagged behind other regions. This gap is particularly evident in sectors like biotechnology and medical sciences, where the potential for transformative innovation is vast, yet the pace of enterprise creation remains slow. The challenge is not just about funding or talent—it’s about systemic barriers that prevent Europe from fully leveraging its intellectual capital.
Uneven Investment and Global Competition
Europe’s scientific excellence is undeniable, but its investment in translating research into market-ready products has not kept pace with the demands of a rapidly evolving global economy. According to the European Commission’s 2025 Biotech Act report, venture capital in health-focused biopharma startups has been overwhelmingly concentrated in the United States. Between 2015 and mid-2025, US-based startups secured over €219 billion in funding, while their European equivalents received only €25 billion—a fraction of the amount. This funding imbalance has allowed American companies to dominate the market, with China emerging as a formidable competitor, capturing nearly 30% of global clinical trials by 2023, compared to the European Economic Area’s decline from 18% in 2013 to 9%.
Why Europe struggles to turn its scientific prowess into profitable ventures is compounded by a lack of cohesive strategy. While individual nations invest in research, the absence of a unified approach creates fragmented ecosystems where startups face hurdles in accessing capital, scaling operations, and navigating regulatory differences. The continent’s scientific legacy is strong, but without a clear pathway to commercialization, many breakthroughs remain confined to academic institutions rather than becoming market drivers.
One of the critical obstacles is the slow pace of regulatory harmonization. In the healthcare sector, for instance, even after a drug is approved within the European Union, distribution across member states is inconsistent. Patients in one country may gain early access to life-saving treatments, while those in another face delays or higher costs. This patchwork system not only hinders medical progress but also deters private investment, as companies are hesitant to commit to markets with uncertain returns.
Fragmented Markets and Unequal Access
Why Europe struggles to turn its scientific strength into economic growth is also tied to the continent’s disjointed market structures. The absence of a truly integrated single market for healthcare innovation means that startups often have to navigate a complex web of national regulations, tax incentives, and reimbursement policies. This fragmentation limits the scalability of European companies, making it harder for them to compete with firms that operate across borders with ease.
“The dream is to create a unified health ecosystem where knowledge, funding, and production flow seamlessly,” says a biomedical entrepreneur based in Berlin. “But right now, Europe feels more like a collection of islands than a single innovation engine.” This sentiment reflects a broader concern: Europe’s scientific potential is being stifled by bureaucratic inefficiencies and a lack of strategic alignment among member states.
Addressing these issues requires more than just policy changes—it demands a cultural shift in how Europe views its role in the global innovation economy. By fostering collaboration between academia, industry, and governments, the continent can create an environment where scientific discoveries are not just celebrated but actively converted into scalable solutions. The Fifth Freedom concept, which promotes the free movement of research and innovation across borders, offers a promising framework, but its implementation remains inconsistent.
Europe’s ability to turn scientific achievements into market success will determine its future competitiveness. With global leaders like the U.S. and China rapidly advancing technologies through aggressive investment and streamlined processes, the continent risks falling further behind. To close this gap, Europe must prioritize creating a cohesive innovation ecosystem that supports both startups and established firms, ensuring that its world-class science translates into tangible economic benefits. The science is there—what’s needed now is the commitment to bridge the gap between discovery and deployment.
